Pliant Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 158
- Market Cap
- $797.1M
- Website
- http://www.pliantrx.com
- Introduction
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-?1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Tang Capital's Concentra Biosciences Acquires Elevation Oncology for $0.36 Per Share in Latest Biotech Liquidation
Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights.
Pliant Therapeutics Cuts Workforce by 45% Following Termination of Idiopathic Pulmonary Fibrosis Trial
Pliant Therapeutics has announced a 45% reduction in its workforce following the termination of its Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF).
PLN-101095 Combined with Pembrolizumab Shows Promising Activity in ICI-Refractory Solid Tumors
Interim data from a Phase 1 trial showed 50% objective response rate in patients receiving PLN-101095 with pembrolizumab at the highest dose tested (1000 mg BID), with confirmed partial responses across multiple tumor types including NSCLC, melanoma, and cholangiocarcinoma.
Pliant Therapeutics Discontinues Phase 2b Trial in Idiopathic Pulmonary Fibrosis
Pliant Therapeutics has announced the termination of their Phase 2b clinical trial evaluating an investigational therapy for idiopathic pulmonary fibrosis, citing strategic portfolio decisions.
Pliant Therapeutics Halts IPF Drug Trial Following Safety Concerns, Stock Plummets
Pliant Therapeutics has suspended enrollment and dosing in their Phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis following safety monitoring board recommendations.
Pliant Therapeutics Halts BEACON-IPF Trial Following Safety Board Review
Pliant Therapeutics has temporarily suspended enrollment and dosing in its Phase IIb/III BEACON-IPF trial of Bexotegrast following recommendations from the independent Data Safety Monitoring Board.
Advanced Liver Cancer Market to Reach $11.13 Billion by 2035, Driven by Early Detection and Novel Therapies
The advanced liver cancer market is projected to grow from $2.31 billion in 2024 to $11.13 billion by 2035, exhibiting a CAGR of 15.38%, according to IMARC Group research.
IPF Drug Development Heats Up with Novel Targets and Clinical Advances
Refoxy Pharma secured $9.58 million to advance its FOXO3-targeting IPF drug, RP-01, aiming to modulate tissue repair mechanisms.